

Form PTO-1449	ATTY DOCKET NO. 0020-4817P	APPLICATION NO. New 09/763985
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)	APPLICANT ITOH et al.	ATTORNEY JOHN J. [Signature]
	FILING DATE February 28, 2001	GROUP # 1 1/2

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS


EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.)

LA	Shichijo et al, "A Gene Encoding Antigenic Peptides of Human Squamous Cell Carcinoma Recognized by Cytotoxic T Lymphocytes" J. Exp. Med, February 2, 1998, Vol. 187, No. 3, pp. 277-288
LB	Gohara "Histocompatibility Leukocyte Antigen-A2402-restricted Cytotoxic T Lymphocytes Recognizing Adenocarcinoma in Tumor-infiltrating Lymphocytes of Patients with Coiono Cancer" Jpn. J. Cancer Res, February 1997, Vol. 88, No. 2, pp. 198-204.
LC	Nagase "Prediction of tha Coding sequences of Unidentified Human Genes. IV. Tha Coding of 40 New Genes (KIAA0121-KIAA0160) Deduced by Analysis of cDAN Clones from Human Cell Line KG-1" J. Clin. Invest., August 1995, Vol. 2, No. 4, pp. 167-174.
LD	Yotnda "Cytotoxic T cell Response Against the Chimeric ETV6-AML1 Protein in Childhood Acute Lymphblastic Leukemia" J. Clim. Invest., July 1998, Vol. 102, No. 2, pp. 455-462.
LE	TAKAHASHI "Recognition of gp43 Tumor-Associated Antigen Peptide by both HLA-A2 Restricted CTL Lines and Antibodiesfrom Melanoma Patients" Cellular Immuunology, June 15, 1997, Vol. 178, No. 2, pp. 162-171.

EXAMINER [Signature]	DATE CONSIDERED 9/11/02
-------------------------	----------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO-1449		ATTY DOCKET NO. 0020-4817P		APPLICATION NO. 09/763,985	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		APPLICANT ITO, Kyogo et al.		ATTACH TO #9	
		FILING DATE February 28, 2001		GROUP UNASSIGNED	
U.S. PATENT DOCUMENTS					
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS
FOREIGN PATENT DOCUMENTS					
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS
OTHER DOCUMENTS (Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.					
53			Rosenberg et al., "Treatment of Patients with Metastatic Melanoma with Autologous Tumor-Infiltrating Lymphocytes and Interleukin 2"; <i>J. of the Natl. Cancer Inst.</i> , Vol. 86, No. 15 (August 1994)		
5			Rammensee et al., "MHC Ligands and Peptide Motifs: First Listing"; <i>Immunogenetics</i> , Vol. 41., pp. 178-228 (1995)		
52			Kubo et al., "Definition of Specific Peptide Motifs for Four Major HLA-A Alleles"; <i>J. of Immunology</i> , Vol. 152, pp. 3913-3924 (1994)		
54			Kondo et al., "Prominent Roles of Secondary Anchor Residues in Peptide Binding to HLA-A24 Human Class I Molecules"; <i>J. of Immunology</i> , Vol. 155, pp. 4307-4312 (1995)		
55			Sudo et al., "Differences in MHC Class I Self peptide Repertoires among HLA-A2 Subtypes"; <i>The J. of Immunology</i> , Vol. 155, pp. 4749-4756 (1995)		
53			Rivoltini et al., "Induction of Tumor-Reactive CTL from peripheral Blood and Tumor-Infiltrating Lymphocytes of Melanoma Patients by In Vitro Stimulation with an Immunodominant Peptide of the Human Melanoma Antigen MART-1"; <i>The J. of Immunology</i> , Vol. 154, pp. 2257-2265 (1995)		
54			Kharkevitch et al., "Characterization of Autologous Tumor-Specific T-Helper 2 Cells in Tumor-Infiltrating Lymphocytes from a Patient with Metastatic Melanoma"; <i>Int. J. Cancer</i> , Vol. 58, pp. 317-323 (1994)		
53			Van Tsai et al., "Identification of Subdominant CTL Epitopes of the GP100 Melanoma-Associated Tumor Antigen by Primary In Vitro Immunization with Peptide-Pulsed Dendritic Cells"; <i>The J. of Immunology</i> , Vol. 158, pp. 1796-1802 (1997)		
53			Altman et al., "Phenotypic Analysis of Antigen-Specific T Lymphocytes"; <i>Science</i> , Vol. 274, pp. 94-96 (Oct. 1996)		
53			Nakao et al., "HLA A2601-restricted CTLs Recognize a peptide Antigen Expressed on Squamous Cell Carcinoma"; <i>Cancer Research</i> , Vol. 55, pp. 4248-4252 (Oct. 1995)		
53			Thomsen et al., "DELIVERY OF MULTIPLE CD8 Cytotoxic T Cell Epitopes by DNA Vaccination"; <i>The J. of Immunology</i> , Vol. 160, pp. 1717-1723 (1998)		
53			KIAA0156 (Genbank Accession No. D63879) 7/10/97		
53			HLA-A2 cDNA (Genbank Accession No. M84379) 1/7/95		
EXAMINER		DATE CONSIDERED			
		9/11/02			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

ATTACHED TO
#8

RECEIVED
FEB 06 2002
TECH CENTER 1600/2900

RECEIVED
FEB 06 2002
TECH CENTER 1600/2900

RECEIVED
FEB 06 2002
TECH CENTER 1600/2900

RECEIVED
FEB 06 2002
TECH CENTER 1600/2900

RECEIVED
FEB 06 2002
TECH CENTER 1600/2900

RECEIVED
FEB 06 2002
TECH CENTER 1600/2900

RECEIVED
FEB 06 2002
TECH CENTER 1600/2900